The team of Professor Zhang Li of the affiliated Xinhua Hospital published an analysis of CD34+ Gan/ZuXi in Circulation Research...

Recently, a team from the Second Department of Cardiology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Professor Zhang Li from the Institute of Cardiovascular Development and Regenerative Medicine, and Professor Xu Qingbo from the First Affiliated Hospital of Zhejiang University School of Medicine published a titled Nonbone Marrow CD34+ on Circulation Research.
The research paper of Cells Are Crucial for Endothelial Repair of Injured Artery uses single-cell transcriptome sequencing and genetic lineage tracing to find the endothelial repair effect of CD34+ cells in situ of non-marrow-derived blood vessels
.

The research group first used single-cell transcriptome sequencing to draw a single-cell map of mouse femoral arteries, analyze the heterogeneity of vascular CD34+ cells, and identify CD34+ cell subgroups with characteristics of stem/progenitor cells; track mice in CD34+ genetic lineage by constructing CD34+ genetic lineages Tracking the pathological changes of CD34+ cells in vivo, it was found that CD34+ cells were involved in the endothelial repair process after the guide wire strained endometrium and exfoliated
.
Furthermore, the research team proved through a bone marrow transplant model that circulating bone marrow-derived CD34+ cells previously considered "endothelial progenitor cells" only form inflammatory cells in the damaged area, while endothelial repair is dominated by non-bone marrow-derived CD34+ cells; combined with selective cells Excluding the model, it was found that the exclusion of non-bone marrow-derived CD34+ cells aggravated the neointimal thickness after injury

In summary, the study focused on the bottleneck of cardiovascular stem cell therapy.
By analyzing the heterogeneity of CD34+ cells and exploring the source of endothelial repair after vascular injury, it innovatively discovered that non-bone marrow-derived CD34+ cells repair the injured vascular endothelium, and pointed out the past stem cell therapy Regardless of stem cell transplantation or cell capture scaffold, the recruited bone marrow circulation-derived CD34+ cells actually aggravate the local inflammation, which is an important reason for the failure of clinical trials
.
Subsequent targeting of non-bone marrow-derived CD34+ cells to promote endothelial repair is a reasonable direction to optimize the clinical transformation of CD34+ stem cell therapy

The first author of this paper is Professor Zhang Li's doctoral student Jiang Lijun, and the co-first authors are Dr.
Chen Ting from the First Hospital of Zhejiang University and Sun Xiaxia, a doctoral student from the Zhang Li team
.
Professor Zhang Li from the Second Department of Cardiology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Institute of Cardiovascular Development and Regenerative Medicine, and Professor Xu Qingbo from the First Hospital of Zhejiang University are the co-corresponding authors